778 related articles for article (PubMed ID: 11786087)
41. Genetic impact of pathogenesis and prognosis of ANCA-associated vasculitides.
Borgmann S; Haubitz M
Clin Exp Rheumatol; 2004; 22(6 Suppl 36):S79-86. PubMed ID: 15675141
[TBL] [Abstract][Full Text] [Related]
42. Brief Report: Circulating Cytokine Profiles and Antineutrophil Cytoplasmic Antibody Specificity in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Berti A; Warner R; Johnson K; Cornec D; Schroeder D; Kabat B; Langford CA; Hoffman GS; Fervenza FC; Kallenberg CGM; Seo P; Spiera R; St Clair EW; Brunetta P; Stone JH; Merkel PA; Specks U; Monach PA;
Arthritis Rheumatol; 2018 Jul; 70(7):1114-1121. PubMed ID: 29693324
[TBL] [Abstract][Full Text] [Related]
43. Antiproteinase 3- and antimyeloperoxidase-associated vasculitis.
Franssen CF; Stegeman CA; Kallenberg CG; Gans RO; De Jong PE; Hoorntje SJ; Tervaert JW
Kidney Int; 2000 Jun; 57(6):2195-206. PubMed ID: 10844589
[TBL] [Abstract][Full Text] [Related]
44. Hypogalactosylation of serum IgG in patients with ANCA-associated systemic vasculitis.
Holland M; Takada K; Okumoto T; Takahashi N; Kato K; Adu D; Ben-Smith A; Harper L; Savage CO; Jefferis R
Clin Exp Immunol; 2002 Jul; 129(1):183-90. PubMed ID: 12100039
[TBL] [Abstract][Full Text] [Related]
45. ANCA: serology in Wegener's granulomatosis.
Pradhan VD; Badakere SS; Ghosh K; Almeida A
Indian J Med Sci; 2005 Jul; 59(7):292-300. PubMed ID: 16062016
[TBL] [Abstract][Full Text] [Related]
46. Clinical significance of ANCA in 98 patients.
Geffriaud-Ricouard C; Noël LH; Chauveau D; Houhou S; Grünfeld JP; Lesavre P
Adv Exp Med Biol; 1993; 336():273-9. PubMed ID: 7905232
[TBL] [Abstract][Full Text] [Related]
47. Inhibition of proteinase 3 by ANCA and its correlation with disease activity in Wegener's granulomatosis.
Daouk GH; Palsson R; Arnaout MA
Kidney Int; 1995 Jun; 47(6):1528-36. PubMed ID: 7643521
[TBL] [Abstract][Full Text] [Related]
48. New advances in the pathogenesis of ANCA-associated vasculitides.
Chen M; Kallenberg CG
Clin Exp Rheumatol; 2009; 27(1 Suppl 52):S108-14. PubMed ID: 19646356
[TBL] [Abstract][Full Text] [Related]
49. Republished: Antineutrophil cytoplasmic antibody-associated vasculitides: is it time to split up the group?
Millet A; Pederzoli-Ribeil M; Guillevin L; Witko-Sarsat V; Mouthon L
Postgrad Med J; 2014 May; 90(1063):290-6. PubMed ID: 24737903
[TBL] [Abstract][Full Text] [Related]
50. Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis.
Lionaki S; Blyth ER; Hogan SL; Hu Y; Senior BA; Jennette CE; Nachman PH; Jennette JC; Falk RJ
Arthritis Rheum; 2012 Oct; 64(10):3452-62. PubMed ID: 23023777
[TBL] [Abstract][Full Text] [Related]
51. Prevalence of antineutrophil cytoplasmic antibodies in a large inception cohort of patients with connective tissue disease.
Merkel PA; Polisson RP; Chang Y; Skates SJ; Niles JL
Ann Intern Med; 1997 Jun; 126(11):866-73. PubMed ID: 9163287
[TBL] [Abstract][Full Text] [Related]
52. Clinicoepidemiological manifestations of RPGN and ANCA-associated vasculitides: an 11-year retrospective hospital-based study in Japan.
Suzuki Y; Takeda Y; Sato D; Kanaguchi Y; Tanaka Y; Kobayashi S; Suzuki K; Hashimoto H; Ozaki S; Horikoshi S; Tomino Y
Mod Rheumatol; 2010 Feb; 20(1):54-62. PubMed ID: 19821007
[TBL] [Abstract][Full Text] [Related]
53. The pathologic spectrum of pulmonary lesions in patients with anti-neutrophil cytoplasmic autoantibodies specific for anti-proteinase 3 and anti-myeloperoxidase.
Gaudin PB; Askin FB; Falk RJ; Jennette JC
Am J Clin Pathol; 1995 Jul; 104(1):7-16. PubMed ID: 7611186
[TBL] [Abstract][Full Text] [Related]
54. Comparison of eight commercial kits for quantitation of antineutrophil cytoplasmic antibodies (ANCA).
Wang G; Csernok E; de Groot K; Gross WL
J Immunol Methods; 1997 Oct; 208(2):203-11. PubMed ID: 9433475
[TBL] [Abstract][Full Text] [Related]
55. [New aspects in ANCA-associated vasculitides].
Lamprecht P
Med Klin (Munich); 2004 Sep; 99(9):518-22. PubMed ID: 15372181
[TBL] [Abstract][Full Text] [Related]
56. Interference of PR3-ANCA with the enzymatic activity of PR3: differences in patients during active disease or remission of Wegener's granulomatosis.
van der Geld YM; Tool AT; Videler J; de Haas M; Tervaert JW; Stegeman CA; Limburg PC; Kallenberg CG; Roos D
Clin Exp Immunol; 2002 Sep; 129(3):562-70. PubMed ID: 12197900
[TBL] [Abstract][Full Text] [Related]
57. Clinical and prognostic features of Korean patients with MPO-ANCA, PR3-ANCA and ANCA-negative vasculitis.
Yoo J; Kim HJ; Ahn SS; Jung SM; Song JJ; Park YB; Lee SW
Clin Exp Rheumatol; 2017; 35 Suppl 103(1):111-118. PubMed ID: 28339364
[TBL] [Abstract][Full Text] [Related]
58. [Antineutrophilic cytoplasmic antibodies (ANCA) in inflammatory rheumatic diseases: immunodiagnostic and immunopathogenetic aspects].
Csernok E; Gross WL
Z Rheumatol; 1995; 54(1):26-38. PubMed ID: 7725808
[TBL] [Abstract][Full Text] [Related]
59. Severe CNS manifestations as the clinical hallmark in generalized Wegener's granulomatosis consistently negative for antineutrophil cytoplasmic antibodies (ANCA). A report of 3 cases and a review of the literature.
Reinhold-Keller E; de Groot K; Holl-Ulrich K; Arlt AC; Heller M; Feller AC; Gross WL
Clin Exp Rheumatol; 2001; 19(5):541-9. PubMed ID: 11579713
[TBL] [Abstract][Full Text] [Related]
60. Clinical presentation and outcome prediction of clinical, serological, and histopathological classification schemes in ANCA-associated vasculitis with renal involvement.
Córdova-Sánchez BM; Mejía-Vilet JM; Morales-Buenrostro LE; Loyola-Rodríguez G; Uribe-Uribe NO; Correa-Rotter R
Clin Rheumatol; 2016 Jul; 35(7):1805-16. PubMed ID: 26852317
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
